• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Cytomegalovirus in hematopoietic stem cell transplant recipients.造血干细胞移植受者巨细胞病毒感染。
Hematol Oncol Clin North Am. 2011 Feb;25(1):151-69. doi: 10.1016/j.hoc.2010.11.011.
2
Cytomegalovirus in hematopoietic stem cell transplant recipients.造血干细胞移植受者中的巨细胞病毒。
Infect Dis Clin North Am. 2010 Jun;24(2):319-37. doi: 10.1016/j.idc.2010.01.008.
3
Coinfection with Human Cytomegalovirus Genetic Variants in Transplant Recipients and Its Impact on Antiviral T Cell Immune Reconstitution.移植受者中人类巨细胞病毒基因变异体的合并感染及其对抗病毒T细胞免疫重建的影响。
J Virol. 2016 Jul 27;90(16):7497-507. doi: 10.1128/JVI.00297-16. Print 2016 Aug 15.
4
Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients.实体器官和造血干细胞移植受者巨细胞病毒病的流行病学
Am J Health Syst Pharm. 2005 Apr 15;62(8 Suppl 1):S7-13. doi: 10.1093/ajhp/62.suppl_1.S7.
5
Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.器官移植感染预防与检测研究中肺和造血细胞移植受者的巨细胞病毒感染：一项多年、多中心前瞻性队列研究。
Transpl Infect Dis. 2018 Jun;20(3):e12877. doi: 10.1111/tid.12877. Epub 2018 Mar 30.
6
Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.来特莫韦用于预防成人巨细胞病毒血清阳性造血干细胞移植受者的巨细胞病毒感染。
Expert Rev Clin Pharmacol. 2018 Oct;11(10):931-941. doi: 10.1080/17512433.2018.1500897. Epub 2018 Sep 18.
7
Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients.心脏和肺移植受者中抗病毒耐药人巨细胞病毒的多样性。
Transpl Infect Dis. 2011 Apr;13(2):145-53. doi: 10.1111/j.1399-3062.2010.00584.x. Epub 2010 Nov 10.
8
Cytomegalovirus Therapy: Role of Letermovir in Prophylaxis and Treatment in Transplant Recipients.巨细胞病毒治疗：来特莫韦在移植受者预防和治疗中的作用。
Annu Rev Med. 2023 Jan 27;74:89-105. doi: 10.1146/annurev-med-042921-124739. Epub 2022 Nov 4.
9
The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation.巨细胞病毒感染对造血干细胞移植受者的临床及经济影响。
Transpl Infect Dis. 2018 Oct;20(5):e12961. doi: 10.1111/tid.12961. Epub 2018 Jul 20.
10
Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection.造血干细胞移植受者巨细胞病毒感染 - 感染的管理。
Expert Rev Hematol. 2016 Nov;9(11):1093-1105. doi: 10.1080/17474086.2016.1242406. Epub 2016 Oct 11.

引用本文的文献

1
When hematology meets ophthalmology: Cytomegalovirus retinitis in pediatric stem cell recipients.当血液学遇上眼科学：儿科干细胞接受者中的巨细胞病毒性视网膜炎
World J Stem Cells. 2025 Jul 26;17(7):107153. doi: 10.4252/wjsc.v17.i7.107153.
2
Cytomegalovirus reactivation in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.接受嵌合抗原受体T细胞疗法治疗的大B细胞淋巴瘤患者的巨细胞病毒再激活
Int J Hematol. 2025 Jun 17. doi: 10.1007/s12185-025-04023-y.
3
Bioequivalent Letermovir Usage for Prophylaxis in Haploidentical Stem Cell Transplantation at High Risk of CMV Reactivation: A Report of Two Cases From India.在巨细胞病毒再激活高风险的单倍体干细胞移植中使用生物等效性来特莫韦进行预防：来自印度的两例报告
Cureus. 2025 Apr 26;17(4):e83035. doi: 10.7759/cureus.83035. eCollection 2025 Apr.
4
Developing a Vaccine Against Human Cytomegalovirus: Identifying and Targeting HCMV's Immunological Achilles' Heel.开发针对人类巨细胞病毒的疫苗：识别并靶向人巨细胞病毒的免疫弱点。
Vaccines (Basel). 2025 Apr 22;13(5):435. doi: 10.3390/vaccines13050435.
5
Clinical Manifestations of Non-Congenital CMV Infection in Infants and Immunocompetent Children: Review of Cases from the Past Decade.婴儿和免疫功能正常儿童非先天性巨细胞病毒感染的临床表现：过去十年病例回顾
Microorganisms. 2025 Mar 28;13(4):772. doi: 10.3390/microorganisms13040772.
6
NFAT single-deficient murine T cells reduce the risk of aGvHD while controlling cytomegalovirus infection.NFAT单缺陷小鼠T细胞在控制巨细胞病毒感染的同时降低了急性移植物抗宿主病的风险。
iScience. 2025 Feb 1;28(2):111937. doi: 10.1016/j.isci.2025.111937. eCollection 2025 Feb 21.
7
Viral Metagenomics in Patients Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): A Brazilian Experience.接受异基因造血干细胞移植（HSCT）患者的病毒宏基因组学：巴西的经验
Microorganisms. 2024 Dec 12;12(12):2557. doi: 10.3390/microorganisms12122557.
8
Viral microRNA regulation of Akt is necessary for reactivation of Human Cytomegalovirus from latency in CD34+ hematopoietic progenitor cells and humanized mice.病毒微小RNA对Akt的调控对于人巨细胞病毒在CD34 +造血祖细胞和人源化小鼠中从潜伏状态重新激活是必要的。
PLoS Pathog. 2024 Dec 11;20(12):e1012285. doi: 10.1371/journal.ppat.1012285. eCollection 2024 Dec.
9
Antiviral potential of Vδ2 T cells in children given TCR αβ/CD19 cell-depleted HLA-haploidentical HSCT.接受TCR αβ/CD19细胞去除的HLA单倍型相合造血干细胞移植的儿童中Vδ2 T细胞的抗病毒潜力
Blood Adv. 2025 Mar 11;9(5):990-1002. doi: 10.1182/bloodadvances.2024013902.
10
Advancements in LAMP-Based Diagnostics: Emerging Techniques and Applications in Viral Detection with a Focus on Herpesviruses in Transplant Patient Management.基于 LAMP 的诊断技术的进展：病毒检测中的新兴技术和应用，重点关注移植患者管理中的疱疹病毒。
Int J Mol Sci. 2024 Oct 26;25(21):11506. doi: 10.3390/ijms252111506.

本文引用的文献

1
Prospective comparison of PCR-based vs late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allo-SCT.异基因造血干细胞移植后患者巨细胞病毒感染的基于 PCR 与基于晚期 mRNA 的抢先抗病毒治疗的前瞻性比较。
Bone Marrow Transplant. 2011 Mar;46(3):408-15. doi: 10.1038/bmt.2010.136. Epub 2010 Jun 28.
2
Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.预处理方案强度对异基因造血细胞移植中巨细胞病毒感染的影响。
Biol Blood Marrow Transplant. 2009 Jun;15(6):694-703. doi: 10.1016/j.bbmt.2009.02.009. Epub 2009 Apr 16.
3
Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease.巨细胞病毒（CMV）抗原血症检测在CMV胃肠道疾病患者中的诊断效能。
Clin Infect Dis. 2009 Jun 15;48(12):e121-4. doi: 10.1086/599116.
4
An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants.通过分析病毒基因组变异评估人巨细胞病毒从供体到受体的传播模式。
J Infect Dis. 2009 Jun 1;199(11):1621-8. doi: 10.1086/598952.
5
The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation.单一及联合激活型杀伤细胞免疫球蛋白样受体基因型对造血细胞移植后巨细胞病毒感染及免疫的影响。
Biol Blood Marrow Transplant. 2009 Mar;15(3):315-25. doi: 10.1016/j.bbmt.2008.11.030.
6
Interlaboratory comparison of cytomegalovirus viral load assays.巨细胞病毒病毒载量检测的实验室间比对
Am J Transplant. 2009 Feb;9(2):258-68. doi: 10.1111/j.1600-6143.2008.02513.x.
7
Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D.在存在UL97基因N597D突变的情况下，缬更昔洛韦成功治疗移植后巨细胞病毒感染。
J Med Virol. 2009 Mar;81(3):507-10. doi: 10.1002/jmv.21397.
8
Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.口服缬更昔洛韦作为抢先治疗对异基因造血干细胞移植受者的巨细胞病毒感染有效。
Int J Hematol. 2009 Mar;89(2):231-237. doi: 10.1007/s12185-008-0249-2. Epub 2009 Jan 17.
9
Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus.缬更昔洛韦作为异基因干细胞移植后巨细胞病毒感染的抢先治疗：对耐药巨细胞病毒出现的影响
J Antimicrob Chemother. 2009 Mar;63(3):600-8. doi: 10.1093/jac/dkn521. Epub 2009 Jan 15.
10
Immunobiology of human cytomegalovirus: from bench to bedside.人类巨细胞病毒的免疫生物学：从 bench 到 bedside。 （注：bench 与 bedside 在这里可能是一种形象说法，bench 可理解为基础研究阶段，bedside 可理解为临床应用阶段，直译为“从实验台到病床边”，意译为“从基础研究到临床应用” ） 准确完整的译文：人类巨细胞病毒的免疫生物学：从基础研究到临床应用
Clin Microbiol Rev. 2009 Jan;22(1):76-98, Table of Contents. doi: 10.1128/CMR.00034-08.

造血干细胞移植受者巨细胞病毒感染。

Cytomegalovirus in hematopoietic stem cell transplant recipients.

机构信息

Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.

出版信息

Hematol Oncol Clin North Am. 2011 Feb;25(1):151-69. doi: 10.1016/j.hoc.2010.11.011.

DOI:10.1016/j.hoc.2010.11.011
PMID:21236396
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3340426/
Abstract

This article examines the clinical manifestations of and risk factors for cytomegalovirus (CMV). Prevention of CMV infection and disease are also explored. Antiviral resistance and management of CMV are examined.

摘要

本文探讨了巨细胞病毒（CMV）的临床表现和危险因素。还探讨了 CMV 感染和疾病的预防。本文还研究了 CMV 的抗病毒耐药性和管理。